title: Anti-thymocyte globulin could improve the outcome of allogeneic hematopoietic stem cell transplantation in patients with highly aggressive T-cell tumors.
abstract: The early experiment result in our hospital showed that anti-thymocyte globulin (ATG) inhibited the proliferation of lymphoid tumor cells in the T-cell tumors. We used the ATG as the part of the conditioning regimen and to evaluate the long-term anti-leukemia effect, the safety and complication in the patients with highly aggressive T-cell lymphomas. Twenty-three patients were enrolled into this study. At the time of transplant, six patients reached first or subsequent complete response, three patients had a partial remission and 14 patients had relapsed or primary refractory disease. The conditioning regimen consisted of ATG, total body irradiation, toposide and cyclophosphamide. The complete remission rate after transplant was 95.7%. At a median follow-up time of 25 months, 16 (69.6%) patients are alive and free from diseases, including nine patients in refractory and progressive disease. Seven patients died after transplant, five from relapse and two from treatment-related complications. The incidence of grades II-IV acute graft-vs-host disease (GvHD) was 39.1%. The maximum cumulative incidence of chronic GvHD was 30%. The most frequent and severe conditioning-related toxicities observed in 8 out of 23 patients were grades III/IV infections during cytopenia. Thus, ATG-based conditioning is a feasible and effective alternative for patients with highly aggressive T-cell tumors.
authors.affiliation: Department of Hematology, Shanghai General Hospital, Shanghai, Jiao Tong University School of Medicine, Shanghai, China.
authors.forename: J
authors.initials: J
authors.lastname: Yang
authors.affiliation: Department of Hematology, Shanghai General Hospital, Shanghai, Jiao Tong University School of Medicine, Shanghai, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Cai
authors.affiliation: Department of Hematology, Shanghai General Hospital, Shanghai, Jiao Tong University School of Medicine, Shanghai, China.
authors.forename: J L
authors.initials: JL
authors.lastname: Jiang
authors.affiliation: Department of Hematology, Shanghai General Hospital, Shanghai, Jiao Tong University School of Medicine, Shanghai, China.
authors.forename: L P
authors.initials: LP
authors.lastname: Wan
authors.affiliation: Department of Hematology, Shanghai General Hospital, Shanghai, Jiao Tong University School of Medicine, Shanghai, China.
authors.forename: S K
authors.initials: SK
authors.lastname: Yan
authors.affiliation: Department of Hematology, Shanghai General Hospital, Shanghai, Jiao Tong University School of Medicine, Shanghai, China.
authors.forename: C
authors.initials: C
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053208:Kaplan-Meier Estimate; D016399:Lymphoma, T-Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000961:Antilymphocyte Serum; D000970:Antineoplastic Agents